Amyris Inc (NASDAQ:AMRS) – Research analysts at B. Riley dropped their Q2 2018 earnings estimates for shares of Amyris in a research note issued to investors on Tuesday, May 15th. B. Riley analyst C. Driscoll now forecasts that the biotechnology company will earn ($0.30) per share for the quarter, down from their previous estimate of ($0.21). B. Riley has a “Buy” rating and a $10.00 price target on the stock. B. Riley also issued estimates for Amyris’ FY2018 earnings at ($1.98) EPS, Q1 2019 earnings at ($0.13) EPS, Q2 2019 earnings at ($0.03) EPS and Q3 2019 earnings at $0.06 EPS.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($1.31). The business had revenue of $23.00 million for the quarter, compared to analyst estimates of $24.12 million. The business’s revenue was up 77.2% on a year-over-year basis. During the same period last year, the firm posted ($0.13) earnings per share.
AMRS stock opened at $5.36 on Friday. The stock has a market cap of $253.44 million, a price-to-earnings ratio of -1.76 and a beta of 0.15. Amyris has a one year low of $1.86 and a one year high of $7.30. The company has a quick ratio of 0.93, a current ratio of 0.98 and a debt-to-equity ratio of -0.54.
In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $6.54, for a total transaction of $622,359.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.30% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning acquired a new position in shares of Amyris during the fourth quarter valued at about $188,000. Element Capital Management LLC acquired a new position in shares of Amyris during the first quarter valued at about $227,000. B. Riley Financial Inc. acquired a new position in shares of Amyris during the first quarter valued at about $294,000. Tibra Equities Europe Ltd acquired a new position in shares of Amyris during the first quarter valued at about $295,000. Finally, Barclays PLC increased its holdings in shares of Amyris by 30,067.8% during the first quarter. Barclays PLC now owns 44,950 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 44,801 shares in the last quarter. Hedge funds and other institutional investors own 19.57% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.